| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
We hypothesized that host CRP directly inhibits cancer progression or metastasis. We inoculated subcutaneously NR-S1M metastatic cells into the backs of mice. Concurrently, recombinant mouse CRP were injected subcutaneously for 5 weeks, after which the mice were killed for evaluation. Immunohistochemical analysis confirmed inguinal lymph node metastasis in 70% (14/20) of control mice, but in only 30% (3/10) of mice in the CRP group. Tumoral lymphangiogenesis was decreased in the CRP group. On the other hand, the F4/80+ macrophage (total macrophages) in the tumor count to be significantly larger in the CRP group, while the relative number of CD206+ anti-inflammatory M2 macrophages was significantly reduced. Furthermore, CRP suppresses expression of N-cadherin, a mesenchymal marker of EMT, and ZEB-1, an EMT-related transcription factor. CRP may thus be a potentially useful tool for preventing cancer progression.
|
